faeciumandS

faeciumandS. of hosts, from invertebrates to mammals, including humans13. When the delicate host bacteria equilibrium is usually disturbed, Enterococcus sp. can cause life-threatening infections, which are often difficult to treat because of multiple intrinsic and acquired antibiotic resistances. Indeed, enterococci are one of the major nosocomial pathogens4,5, as they very easily infect patients with recent medical procedures, organ transplantation, diabetes, malignancy, and renal insufficiency6,7.E. faeciuminfections have high rates of antibiotic resistance and mortality8, with more and more strains able to resist to most clinically available antibiotics9,10. The World Health Organisation (WHO) has therefore declared vancomycin-resistantE. faecium(VREfm) a threat to humankind for which rapid actions are needed11,12. Prevention of these infections through vaccines can reduce the usage of antibiotics, and decrease lengths of hospitalisations13. Several vaccine antigen candidates againstE. faeciumhave been investigated1420, but there is so much no vaccine clinically available21. Indeed, WHO has broadly categorised bacterial pathogens in four Pipeline Feasibility groups (A-D) in terms of feasibility of vaccine development, based on the progression of vaccine candidates in clinical and preclinical development22. In this classification,E. faeciumbelongs to Pipeline Feasibility Group D (low), including hard AMR priority pathogens for which no vaccine candidate has been recognized in clinical or preclinical development22. Pathogenic bacteria need to hunt for Zn through Zn-binding proteins23to be Mal-PEG2-VCP-Eribulin able to survive in the host inhospitable environment and counteract the host-derived Zn limitation24. Consistently, mutations in Zn-regulating genes impair virulence and increase susceptibility to the host defence machinery in several bacterial species2529. InE. faecium, Zn homoeostasis is usually regulated by the surface-exposed lipoprotein AdcA, a member of substrate-binding proteins (SBPs) of ATP-binding cassette (ABC) transporters which is usually upregulated during contamination18. Similarly, the core genome ofE. faecalisencodes a conserved AdcACB system and an orphan substrate-binding lipoprotein AdcAII30. Inactivation of genes encoding these proteins results in severe growth and survival defects and a decreased resistance to ampicillin, bacitracin, and daptomycin30. Analogous Zn uptake mechanisms have been observed inS. aureus, which possesses two ABC transporters for Zn acquisition, CntABCDF and AdcABC; whose simultaneous deletion results in growth impairment under Zn-restricted conditions and attenuated virulence31. Besides contributing to Zn homoeostasis, AdcA ofS. aureuswas shown to bind human plasminogen and the human negative match regulator factor H (FH), and thus may supportS. aureusinvasion and colonisation31. AdcA ofE. faeciumhas been proven to Mal-PEG2-VCP-Eribulin elicit specific, opsonic, and protective antibodies, with considerable cross-reactivity and serotype-independent protection among the homologous strainE. faeciumE155 and the clinical isolatesE. faeciumE1162,E. faecalis12030, type 2 and type 518. The observed antigenicity of AdcA lipoprotein, its specific location, and its crucial role in many bacterial species, Mal-PEG2-VCP-Eribulin make AdcA a stylish candidate for vaccine development. In this study, we used a structural vaccinology approach to develop an AdcA-based vaccine antigen, here denoted as Sc(EH)3, with a cross-reactive potential against several Gram-positive pathogens. To achieve this goal, we designed and computationally validated Sc(EH)3; then, we recombinantly produced the novel molecule and Mal-PEG2-VCP-Eribulin tested it for its properties and efficacy. Sc(EH)3is a multi-epitope presenting compact protein (of 22 kDa) with outstanding stability to storage and temperature, being highly stable at room heat. Most important, Sc(EH)3elicits in rabbits opsonic and protective antibodies that are effective against Gram-positive pathogens, includingE. faecium, E. faecalisandS. aureus. == Results == == Anti-AdcA serum mediates Opsonophagocytic killing of differentS. aureusstrains == Given the crucial role of the surface-exposed lipoprotein AdcA inS. aureus(which shares with AdcA ofE. faeciuma sequence identity of 66%) and the important challenge of addressing vaccine development against MRSA32,33, we tested whether antibodies raised against AdcA fromE. faeciumwere also able to mediate Mal-PEG2-VCP-Eribulin opsonophagocytosis in three differentS. aureusstrains including MW2, Reynolds and LAC. We selected MW2 and Reynolds strains because they express dominant polysaccharide capsule, CP5 and CP8 respectively, among HSPC150 clinical isolates. AlsoS. aureusUSA300 (LAC), which lacks a capsule, is usually prevalent in the United Says34. To obtain antibodies, New Zealand rabbits were previously immunised via intramuscular injection with recombinantly expressed AdcA fromE. faeciumand sera made up of anti-AdcA antibodies were collected as explained (Fig.1A, B)18. In an opsonophagocytic killing assay (OPKA) we observed that anti-AdcA was, indeed, opsonic against all testedS. aureusstrains, with percentages of opsonophagocytic killing mediated by the anti-AdcA serum in the range 4060%, compared with.